Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
isrib In conclusion the partial sequencing and characterizat
2023-12-01

In conclusion, the partial sequencing and characterization of R. quelen cyp19a1b provides essential information about this gene and its presence in peripheral tissues outside of the central nervous system in a teleost. Furthermore, we covered sex differences in the effects of E2 on the cyp19a1b gene
-
In summary these data show that agonist exposure induces int
2023-12-01

In summary, these data show that agonist exposure induces internalization and reduction in cell surface HA-mAPJ expression that occurs relatively rapidly during agonist exposure and recovers more slowly after agonist removal. Moreover the ppERK response of mAPJ-HEK293 cells to [Pyr1]apelin-13 desens
-
br Conclusions The present protocol for localizing
2023-12-01

Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A
-
Although the interactions of PhLP with G and its
2023-12-01

Although the interactions of PhLP with Gβγ and its other partners have been convincingly documented through in vitro studies, it is not clear how PhLP controls CAY10603 signaling in vivo. C. elegans provides a powerful genetic model to analyze Phosducin function and study its interacting partners i
-
In humans the superior safety profile of lipid
2023-12-01

In humans, the superior safety profile of lipid-associated formulations is characterized by decreased acute infusion-related reactions and dose-related nephrotoxicity, allowing the administration of larger doses and therefore similar efficacy with fewer administrations. In vitro studies and human cl
-
Angiogenesis is a process of
2023-12-01

Angiogenesis is a process of formation of new vessels from arterial vascularization created by endothelial cells. It is essential for the continuous growth of the tumor because it supplies the tumor with nutrients and oxygen, and eliminates cellular waste, which can be toxic to cancer cells [8]. Inf
-
Our surprising results show that AAD treated
2023-12-01

Our surprising results show that AAD-treated tumors adjacent to adipose tissues and in steatotic liver continue to grow in the presence of a minimal number of microvessels. In non-adipose tumor models, the similar degree of vascular suppression is translated into marked suppression of tumor growth.
-
br Experimental section br Abbreviations
2023-12-01

Experimental section Abbreviations PSA, puromycin–sensitive aminopeptidase; APN, aminopeptidase N; AML, acute myeloid Leukemia; ALL, acute lymphoblastic leukemia; AADR, amino Tranexamic Acid deprivation response; PAN, puromycin aminonucleoside; DCC, dicyclohexyl carbodiimide; NHS, N–hydroxy s
-
These results validate the docked pose of the
2023-11-30

These results validate the docked pose of the ALR2-3e complex in comparison to the docked complex of the ALR2-4c complex of which the compound docked completely out of the binding pocket of ALR2 (). This concludes to that the removal of the acetic SC 79 moiety leads to inactive or weakly active ta
-
br Discussion With recently improved
2023-11-30

Discussion With recently improved understanding of the role of βARK1 in the progression of HF and as a potential therapeutic target in HF, we explored the relationship between plasma βARK1, as a marker of chronic sympathetic overactivation, and physical symptoms in HF. Our main findings were 1) e
-
Unlike AK inhibition the inhibition of ADA activities
2023-11-30

Unlike AK inhibition, the inhibition of ADA activities by EHNA had little effect on spinal reflex potentials, although EHNA did increase extracellular adenosine levels. One explanation for this discrepancy is that the adenosine increase seen herein was not sufficient to inhibit reflex potentials. In
-
It is already established in the literature
2023-11-30

It is already established in the literature that products synthesized by 5-LO, such as lipoxin A4, can activate PPARγ in a setting of experimental stroke [43]. Interestingly, experiments using 5-LO knockout mice in an endotoxemia model to mimic septic conditions, demonstrated reduced multiple organ
-
Nevertheless though the LO pathway dictates the production
2023-11-30

Nevertheless, though the 5-LO pathway dictates the production of lipid mediators with opposite roles in the immune reactions, like LTs and LXA4 [32], our results seemed to corroborate others that pointed to LTB4 as an outstanding mediator involved in persistent and chronic inflammatory skin diseases
-
The synthesis and secretion of adrenal androgens is apparent
2023-11-30

The synthesis and secretion of adrenal androgens is apparently unique to humans and nonhuman primates, and requires the expression of key mediators such as CYP17 [26]. Endocrine control of CYP17 expression in rhesus monkeys is comparable to that in humans [27]. An analysis of baboon cDNA for CYP17 s
-
br Perspective AA LA and other PUFAs
2023-11-30

Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
15768 records 229/1052 page Previous Next First page 上5页 226227228229230 下5页 Last page